Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States

Intensive chemotherapy (IC) is commonly used to achieve remission in patients with acute myeloid leukemia (AML). Venetoclax plus azacitidine (VEN-AZA) is FDA-approved to treat patients with AML aged ≥ 75 years or who are ineligible for IC. This retrospective analysis used de-identified electronic he...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeidan, Amer M., Pollyea, Daniel A., Borate, Uma, Vasconcelos, Alberto, Potluri, Ravi, Rotter, David, Kiendrebeogo, Zephirin, Gaugler, Lona, Prebet, Thomas, Strocchia, Maria, Bonifacio, Gaetano, Chen, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285011/
https://www.ncbi.nlm.nih.gov/pubmed/36732419
http://dx.doi.org/10.1007/s00277-023-05109-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285011/
https://www.ncbi.nlm.nih.gov/pubmed/36732419
http://dx.doi.org/10.1007/s00277-023-05109-5

Ejemplares similares